Travere Therapeutics (TVTX) Convertible Debt (2011 - 2026)

Travere Therapeutics' Convertible Debt history runs 15 years deep, the most recent figure standing at $312.1 million for Q1 2026.

• Quarterly Convertible Debt changed 0.46% year-over-year to $312.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.1 million (changed 0.46% YoY) and the FY2025 annual result came in at $311.7 million, changed 0.46% from the prior year.
• Convertible Debt was $312.1 million for Q1 2026 at Travere Therapeutics, roughly flat from $311.7 million in the prior quarter.
• Across five years, Convertible Debt topped out at $378.1 million in Q2 2024 and bottomed at $310.0 million in Q3 2024.
• A 5-year average of $349.4 million and a median of $374.7 million in 2022 frame the typical range for Convertible Debt.
• Annual changes were most pronounced in 2022 — Convertible Debt surged 71.65% — and 2025, when it dropped 17.75%.
• Travere Therapeutics' Convertible Debt stood at $375.5 million in 2022, then rose by 0.46% to $377.3 million in 2023, then dropped by 17.75% to $310.3 million in 2024, then climbed by 0.46% to $311.7 million in 2025, then increased by 0.11% to $312.1 million in 2026.
• Business Quant data shows TVTX's Convertible Debt at $312.1 million in Q1 2026, $311.7 million in Q4 2025, and $311.4 million in Q3 2025.